GlassScriptPhysician profile
John L Swan
NPI 1336124742
$6,147.33
in general payments reported to CMS, 2019-2025
26 companies · $776 in 2025
The $776 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $904 · 2021: $468 · 2022: $1,155 · 2023: $564 · 2024: $498 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,837.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $1,375.72 | 2019-2021 | |
| Alcon Vision LLC | $899.91 | 2019-2025 | Rocklatan, Clareon, Unity |
| Allergan, INC. | $570.51 | 2019-2022 | |
| Abbvie INC. | $486.97 | 2022-2025 | Durysta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $466.45 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $466.34 | 2019-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $457.15 | 2019-2025 | Tecnis Simplicity, Amo Phaco Needle |
| Bausch & Lomb Americas INC. | $253.10 | 2022-2025 | Vyzulta, Miebo, Lotemax Sm |
| Ocular Therapeutix, INC. | $226.41 | 2019-2023 | Dextenza |
| Eyevance Pharmaceuticals LLC | $134.21 | 2020-2022 | |
| Ivantis, INC | $119.99 | 2019-2021 | |
| Beaver-Visitec International, INC. | $108.23 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $97.58 | 2024-2025 | Xdemvy |
| Rxsight INC | $86.86 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $80.59 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $65.00 | 2025 | |
| Oyster Point Pharma, INC. | $47.58 | 2022 | |
| Harrow Eye, LLC | $35.13 | 2025 | Vevye |
| Sight Sciences, INC. | $24.95 | 2022 | |
| Alcon Research LLC | $23.47 | 2019 | |
| Ani Pharmaceuticals, INC. | $23.04 | 2025 | Purified Cortrophin Gel |
| Glaukos Corporation | $22.02 | 2025 | Idosetr |
| New World Medical,INC. | $21.79 | 2023 | |
| Dompe US, INC. | $21.59 | 2022 | |
| Aerie Pharmaceuticals, INC. | $16.60 | 2021 | |
| Akorn Operating Company LLC | $16.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Swan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.